ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Update

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 57,777 shares, a drop of 40.1% from the June 30th total of 96,526 shares. Approximately 1.8% of the shares of the stock are short sold. Based on an average daily volume of 68,640 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

A number of institutional investors and hedge funds have recently modified their holdings of SBIO. Steward Partners Investment Advisory LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at about $26,000. Comerica Bank acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the third quarter worth approximately $27,000. Harbor Investment Advisory LLC purchased a new position in ALPS Medical Breakthroughs ETF during the second quarter valued at approximately $29,000. Global Retirement Partners LLC acquired a new position in ALPS Medical Breakthroughs ETF in the 4th quarter valued at approximately $34,000. Finally, Raymond James Financial Inc. acquired a new position in ALPS Medical Breakthroughs ETF in the 2nd quarter valued at approximately $82,000.

ALPS Medical Breakthroughs ETF Stock Performance

NYSEARCA:SBIO opened at $63.36 on Friday. ALPS Medical Breakthroughs ETF has a twelve month low of $32.35 and a twelve month high of $69.34. The company has a 50-day moving average of $59.65 and a 200-day moving average of $54.88.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.